RE:RE:RE:RE:84 percent upside sounds like another year of waiting ...
[be quote=SPCEO1]I have not seen the report either but he did give TH credit for a 25% chance of approval for NASH.
None of the analysts are giving any credit in their price targets for cancer but without data, they really cannot do so yet. I don't think the stock will be given much credit for cancer until the phase 1b results are in, assuming they show the drug actually works.
scarlet1967 wrote: I fully agree, I haven't seen the report but I bet despite positive comments about R&D programs there is very little or nothing priced in his analysis for any of the programs.
FredTheVoice wrote: Interesting,
But as other here mentionned, if cancer plateform is promising, 100% upside is just the very low of what we will see stock-wise.....
And what I think is that a lot of the board member here wont be able to enjoy the ride to 30$C......
FTV.
[/quote]